Data on oncology patients is rapidly changing – so it’s no wonder that there’s a significantly increasing need for advanced databases to house this information as quickly and efficiently as possible. Why? The goal is to achieve targeted therapeutic efficacy. An important therapeutic channel for oncology patients is through clinical trials – approved experiments done in clinical research that generate data on safety and efficacy.
Still, today data often isn’t readily reported and gaining relevant information in a clinically acceptable timeframe is a difficult task to accomplish, which in turn creates issues between patients and appropriate therapeutic options. In an essay titled, The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies, Susan M. Mockus states, “Through queries of data housed in JAX-CKB, we have analyzed the landscape of clinical trials relevant to our 358-gene targeted sequencing panel to evaluate strengths and weaknesses in current molecular targeting in oncology. Through this analysis, we have identified patient indications, molecular aberrations, and targeted therapy classes that have strong or weak representation in clinical trials.”
JAX-CKB contains the most up-to-date information regarding clinical trial status by pulling data from clinicaltrials.gov for any change to recruitment status – only clinical trials that have open recruitment statuses are included on clinical reports. This connects patients to trials relevant to the therapy they are seeking and may have unintentional, beneficial consequences of increasing success and development of targeted agents by prescreening patients outside of the clinical trial protocol for the presence of relevant genomic targets.
Patient treatment in oncology is dependent on a total understanding between molecular variants in tumors and efficacy, and the ability to access clinically relevant information as quickly and efficiently as possible only helps the patient make progress in their treatment. Access to the various points of information, along with the means to share such information across different information systems thus becomes the ambitions goal.
With the same foundational goal of maximized interoperability, Adaptive Clinical Systems aims to help clinical trial operations in their pursuit of improving clinical trials with improved database efficiencies that lead to better patient treatment.
Whether you’re a CRO, Trial Sponsor (Pharmaceutical or Biotechnology Company), Investigator-Initiated Trial, Hospital or Academic Research Center, or a Core Laboratory struggling with integration of clinical study data from multiple systems and platforms, Adaptive Clinical Systems offers a simple, secure, validated, compliant (FDA CFR 21 Part 11 and GxP), and cost-effective solution for clinical data integration.
Interested in The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies
Want to read the full article by Susan M. Mockus?